KeyOptions announces the appointment of Dr. Kerry Mills as Chair of the ‘International Virolens Research Consortium.
PRESS RELEASE: KEY OPTIONS
SYDNEY AUSTRALIA – September 2, 2021:
KeyOptions announces the appointment of Dr. Kerry Mills as Chair of the ‘International Virolens Research Consortium’.
KeyOptions, an Australian technology company, today announced the appointment of Dr. Kerry Mills to the International Virolens Research Consortium (IVRC) Board of Directors, effective September 6, 2021.
Dr. Mills will serve as the IVRC Chair and will take the reins during this critical period as the Consortium is established. Dr. Mills will also act as temporary head to the IVRC Scientific Committee of the Board.
Dr. Mills has held senior scientific posts within industry and Heidelberg University and is currently the Director of Systematic Solutions Pty Ltd. She is an expert in systematic review and meta-analysis and provides scientific evaluation, advice and training to industry, government and academia.
INTERNATIONAL VIROLENS RESEARCH CONSORTIUM – IVRC.
The IVRC will foster collaborative research among the Virolens’ community generally and in the field of varieties of COVID testing methods and screening. The IVRC will host workshops, conferences and guest lectures. It will provide results including clinical trials and research and will arrange update sessions on the most recent papers and research matters; all with a particular focus on the Virolens’ technology.
‘I am delighted that a scientist with such esteem and scientific credibility will now lead the IVRC as Chair’ said Gavin Milton-White, Chief Commercial Officer for KeyOptions. ‘With Dr. Mills extensive expertise within virology, not to mention her broad scientific credibility, she is ideally placed to lead the Consortium’s discussions around the Virolens technology and will prove pivotal in this important stage of the Consortium’s formation.’
Dr Mills will also temporarily lead the IVRC Scientific Committee; the committee consists of independent experts, will present analyses to the Virolens partners (and the wider community) and advise them on how their deployment and testing programmes might be aligned, improved and implemented.
